Keypoints:
• TALAPRO-2: An in-depth discussion on the role of PARP inhibitors in prostate cancer, focusing on the study's design, findings, and the importance of germline and NGS testing.
• NIAGARA Update: Insights into the new standard of care for resectable muscle-invasive bladder cancer and the promising results from the perioperative approach with Durvalumab.
• CheckMate-9ER Update: A look at the combination of Cabozantinib and Nivolumab in first-line metastatic RCC, including the latest findings and implications for treatment beyond the first line.
• TiNivo2: Exploring Tivozanib’s role in the RCC treatment landscape and potential sequencing strategies.
In this episode of the Oncology Brothers podcast, we had the pleasure of welcoming Dr. Toni Choueiri, a distinguished GU medical oncologist from Dana-Farber Cancer Institute. Our discussion focused on the key highlights from the GU-ASCO 2025 conference, covering significant studies in prostate, bladder, and renal cell carcinoma.
We kicked off with the TALAPRO-2 study, presented by Dr. Neeraj Agarwal, which examined the role of PARP inhibitors in first-line castration-resistant prostate cancer. Dr. Choueiri emphasized the importance of germline and somatic mutation testing, noting that while the overall survival benefit was significant, the majority of the positive outcomes were seen in patients with HRR mutations. We discussed the implications of these findings and the need for shared decision-making when considering PARP inhibitors due to their potential side effects.
Next, we delved into the NIAGARA study update in bladder cancer, where Dr. Choueiri highlighted the promising results of the perioperative approach with Durvalumab. Although not yet FDA approved, many clinicians are beginning to adopt this regimen, especially for patients eligible for cisplatin therapy. The discussion underscored the importance of achieving pathologic complete response (CR) and its correlation with event-free survival.
We then transitioned to renal cell carcinoma, discussing the CheckMate-9ER trial, which evaluated the combination of cabozantinib and nivolumab. Dr. Choueiri shared encouraging updates on overall survival and progression-free survival, reinforcing the efficacy of this combination as a first-line treatment option. We also touched on the TiNivo-2 study, which explored the re-challenge of nivolumab in patients who had previously progressed on immunotherapy, although the results were not as favorable as hoped.
Throughout the episode, we emphasized the evolving landscape of cancer treatment, particularly the integration of immunotherapy and targeted therapies across various cancer types. Dr. Choueiri's insights provided valuable perspectives on the current state of GU oncology and the importance of personalized medicine.
As always, we hope you find these discussions helpful in your practice. If you enjoyed this episode, please share it with colleagues and consider leaving us a review to help us reach more oncologists. Thank you for tuning in to the Oncology Brothers podcast!
Listen Podcast on Your Favourite Platform
